Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on developing gene therapies for cardiovascular diseases caused by genetic mutations. Its core programs target conditions like Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, hypertrophic cardiomyopathy, and neurodegenerative disorders such as Alzheimer’s disease. Utilizing AAV vector technology, the company aims to address underlying genetic causes, offering potentially transformative, disease-modifying treatments for high unmet medical needs in large patient populations.
This description was generated via AI from an annual report. Updated about 1 year ago.